Advertisement

Covaxin demonstrates protection against new variants

Follow The Hawk on Google News+ Follow

Advertisement


New Delhi: Bharat Biotech's Covaxin retained neutralising activity against emerging variants of coronavirus, as per a new study.

A study published by Clinical Infectious Diseases found that vaccination with Covaxin produced neutralising titres against all key emerging variants tested including B1617 and B117, first identified in India and the UK, respectively.

Advertisement

A modest reduction in neutralisation by a factor of 1.95 was observed against B1617 variant compared to vaccine variant.

Also readFSSAI to initiate action against Bisleri over unsafe water sample

Despite this reduction, neutralising titre levels with B 1617 remain above levels expected to be protective.

No difference in neutralisation between B 117 first identified in the UK and vaccine strain was observed.

Advertisement

The study was conducted in collaboration with National Institute of Virology and Indian Council of Medical Research.

—IANS

Get The Hawk first on Google

Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.

Share this story

Advertisement

India eyes space-based drug development as scientists, startups explore microgravity researchRead next →India eyes space-based drug development as scientists, startups explore microgravity researchHealth · 22 Nov 2026, 03:08 PM IST